Jesduvroq (daprodustat) / GSK, Kyowa Kirin - LARVOL DELTA

A Case of Post-Transplant Lymphoproliferative Disorder with Suspected Thrombosis Leading to Discontinuation of Daprodustat Following Pharmacist Intervention (PubMed, Gan To Kagaku Ryoho) - "The treatment course comprised R-CHOP chemotherapy. However, because daprodustat is known to pose some risk to patients with thromboembolic disease, the pharmacist provided the attending physicians with information relevant to the discontinuation of daprodustat. Subsequently, the patient was diagnosed with left lower-extremity deep vein thrombosis, and daprodustat was discontinued."

Journal • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pulmonary Disease • Thrombosis • Transplantation

Dose Conversion Ratio Between Roxadustat and Daprodustat in Patients With Non-dialysis Chronic Kidney Disease. (PubMed, Cureus) - "Our study results suggest that the dose conversion ratio between roxadustat and daprodustat is approximately 10:1 in non-dialysis CKD patients."

Journal • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Hepcidin and Cardiovascular Events in CKD With and Without Dialysis. (PubMed, Kidney Int Rep) - "In nondialysis patients with CKD, a nonlinear relationship was observed between baseline hepcidin levels and MACE, whereas no association was found in dialysis patients. Baseline hepcidin levels did not modify the treatment effect of daprodustat compared with ESAs, irrespective of dialysis status, suggesting limited utility of hepcidin for guiding treatment selection."

Journal • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease • CRP

Detection and confirmation of hypoxia-inducible factor activating agents in equine plasma and urine by liquid chromatography coupled to mass spectrometry. (PubMed, J Chromatogr A) - "LOC was 50 to 200 pg/mL for all analytes in plasma, except daprodustat and IOX 3 at 500 pg/mL, and 20 to 500 pg/mL in urine, except daprodustat and IOX 3 at 1000 pg/mL. The developed LC-MS method was successfully applied to the analysis of plasma and urine samples from a research horse following oral administration of JNJ 42041935."

Journal • EPO

Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: Services Hospital, Lahore

New trial • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia (clinicaltrials.gov) - P2 | N=15 | Terminated | Sponsor: GlaxoSmithKline | Phase classification: P2a ➔ P2

Phase classification • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Association Between Perioperative Daprodustat Use and Early Posttransplant Graft Function in Living Donor Kidney Transplantation: A Propensity Score-Matched Retrospective Study. (PubMed, Curr Ther Res Clin Exp) - "No delayed graft function or thrombotic events occurred, and rejection did not differ between groups. These findings raise the possibility that perioperative daprodustat use may be associated with improved early graft function in LDKT, warranting further investigation."

Journal • Retrospective data • Cardiovascular • Inflammation • Reperfusion Injury • Transplantation

Safety of Daprodustat for the Treatment of Chronic Kidney Disease Anemia: Final Analysis of a Multicenter Postmarketing Surveillance Study in Japan. (PubMed, Ther Apher Dial) - "No new safety concerns were identified for daprodustat in the real-world setting in Japan."

Journal • P4 data • Anemia • Autosomal Dominant Polycystic Kidney Disease • Cardiovascular • Chronic Kidney Disease • Genetic Disorders • Hematological Disorders • Hypertension • Nephrology • Oncology • Polycystic Kidney Disease • Renal Disease • Retinal Disorders

Association of nutritional indices with hyporesponsiveness to hypoxia-inducible factor-prolyl hydroxylase inhibitors in patients with chronic kidney disease: a single-center retrospective observational study. (PubMed, BMC Nephrol) - "Malnutrition, which is closely associated with anemia, may contribute to the reduced responsiveness to HIF-PHIs. A high HRI may be undesirable for any patient because of safety concerns and economic burden."

Journal • Observational data • Retrospective data • Chronic Kidney Disease • Hematological Disorders • Inflammation • Nephrology • Renal Disease

Cost-effectiveness evaluation of renal anemia treatment with the use of HIF-PF inhibitors (ERA 2026) - "Method In 31 outpatient hemodialysis patients (22 males, 9 females, mean age 70.2 years, average dialysis history 81 months) who maintained Hb concentrations ≥ 11.0 g/dL for more than half a year with ESA preparation (Darbepoetin alfa 10 μ ~ 20 μ /week) were treated with HIF-PH inhibitors (Daprodustat 6mg) after obtaining written consent, were taken orally on the day of dialysis treatment, and the cost reduction effect and anemia maintenance effect (change in Hb concentration) were examined for 6 months before and 6 months after administration. It is important to treat renal anemia considering the patient's pathological conditions and medical drug price. Image"

Cost effectiveness • HEOR • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Daprodustat augments red cell and γ-globin production in models of sickle cell disease. (PubMed, Blood Red Cells Iron) - "In addition to these systemic, non-cell-autonomous effects on iron homeostasis, daprodustat directly induces γ-globin expression and increases the production of fetal hemoglobin-containing erythroid cells (F-cells) derived from CD34+ hematopoietic stem and progenitor cells of patients with SCD, conferring cell-autonomous therapeutic benefits. These findings demonstrate that HIF-PHIs act on multiple therapeutic targets in SCD and represent a promising oral treatment option for chronic anemia in this disease."

Journal • Genetic Disorders • Hematological Disorders • Nephrology • Renal Disease • Sickle Cell Disease • CD34

LC-PDA & LC-MS/MS approach of Daprodustat: Forced degradation study. (PubMed, Xenobiotica) - "This method can clearly depict the stability of daprodustat under the influence of various environmental factors in less time with low cost. Further, this study also helps in impurity profiling studies."

Journal • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Iron deficiency and risk of heart failure and cardiovascular events in CKD: Insights from the ASCEND-ND trial. (PubMed, Eur J Heart Fail) - "Iron deficiency defined by low transferrin saturation, but not low ferritin levels, is associated with increased risk of heart failure and cardiovascular death in CKD, independent of hemoglobin."

Journal • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Hematological Disorders • Metabolic Disorders • Nephrology • Renal Disease

Thrombosed epic mitral bioprosthesis in the late postoperative period: A case report. (PubMed, J Cardiol Cases) - "Postoperatively, anticoagulation therapy with warfarin was initiated. In this case, discontinuation of edoxaban combined with initiation of daprodustat likely contributed to BVT. These findings underscore the importance of maintaining long-term anticoagulation in patients with risk factors for BVT and of carefully monitoring for thrombotic events in patients receiving hypoxia-inducible factor prolyl hydroxylase inhibitors."

Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Disorders • Thrombosis

Hypoxia inducible factors regulate pneumovirus replication by enhancing innate immune sensing. (PubMed, Proc Natl Acad Sci U S A) - "Mechanistically, daprodustat reduced N6-methyladenosine modification of viral RNA through upregulation of RNA demethylases, promoting detection by innate immune sensors. This study highlights the intricate interplay between hypoxia and antiviral immunity and offers valuable insights into pneumovirus-host interactions and potential therapeutic interventions."

Journal • Infectious Disease • Pneumonia • Respiratory Diseases • Respiratory Syncytial Virus Infections • ISG15

REAL-WORLD ANEMIA MANAGEMENT BEFORE HEMODIALYSIS INITIATION IN JAPAN: A RETROSPECTIVE MULTICENTER COHORT STUDY (ISN-WCN 2026) - "ESA was used in 60%, HIF-PHIs in 30%, and no erythropoietic agents in 10%, with the following distribution: darbepoetin alfa 34%, epoetin beta pegol 26%, daprodustat 25%, roxadustat 3%, vadadustat 1%, and enarodustat 1%. In a multivariate logistic regression model adjusted for sex, age, and transferrin saturation, lower Hb 6 months prior was independently associated with Hb < 9 g/dL at HD initiation (p < 0.001), without significant differences between ESA and HIF-PHI groups.Conclusion Despite contemporary anemia therapy, 60% of patients presented with Hb < 10 g/dL and one-third with Hb < 9 g/dL at HD initiation. Lower baseline Hb strongly predicted suboptimal Hb control, suggesting that earlier dose adjustment and closer monitoring are warranted during progression to end-stage kidney disease."

Real-world • Real-world evidence • Retrospective data • Acute Kidney Injury • Anemia • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetic Nephropathy • Glomerulonephritis • Heart Failure • Hematological Disorders • Lupus Nephritis • Nephrology • Renal Disease • STAT3

EFFICACY OF HIF-PHD INHIBITORS FOR RENAL ANEMIA IN PERITONEAL DIALYSIS PATIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY (ISN-WCN 2026) - "Among 49 PD patients treated with HIF-PHD inhibitors daprodustat or vadadustat, 15 patients met the inclusion criteria:(1) switched from ESA therapy (patients with prior HIF-PHD inhibitor or without prior ESA use were excluded) and (2) baseline Hb < 11 g/dL. The improvement was particularly evident among those with baseline Hb < 10 g/dL. These findings support the clinical utility of HIF-PHD inhibitors as an effective alternative to ESA therapy in PD populations though larger prospective studies are warranted."

Retrospective data • Anemia • Hematological Disorders

OUTCOME OF DAPRODUSTAT IN BANGLADESHI NON DIALYSIS CKD PATIENTS (ISN-WCN 2026) - "Treatment with Daprodustat was cost effective as Darbepoetin costs 8000 to 16000 BDT per month ( USD 65 to 130 USD ) and Daprodustat costs only 2700 to 4200 BDT ( USD 22 to 34) per month in Bangladesh.Conclusion Daprodustat can be a cost effective treatment of non dialysis CKD patients in Bangladesh. Larger studies needed to evaluate its efficacy and side effects in non dialysis CKD patients on Bangladeshi Population."

Clinical • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Diabetic Retinopathy • Heart Failure • Retinal Disorders

HEPCIDIN AND CARDIOVASCULAR EVENTS IN CHRONIC KIDNEY DISEASE WITH AND WITHOUT DIALYSIS: POST HOC ANALYSIS OF THE ASCEND-ND AND ASCEND-D TRIALS (ACC 2026) - " This is a post-hoc analysis of the Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) trial, and the Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) trial; 2 randomized, open-label, phase 3 trials to test the efficacy and safety of daprodustat compared with conventional erythropoiesis-stimulating agents... In patients with CKD not undergoing dialysis, a U-shaped relationship was observed between baseline hepcidin levels and MACE, while no association between hepcidin levels and MACE was observed in patients with CKD undergoing dialysis."

Retrospective data • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Myocardial Infarction • Nephrology • Renal Disease • CRP

Prolyl hydroxylase inhibitors, roxadustat and daprodustat, inhibit platelet activation and thrombosis through the PI3K/AKT/HIF-1α pathway. (PubMed, Biochem Pharmacol) - "Our study revealed the pharmacological effects of roxadustat and daprodustat in inhibiting platelet activation and thrombosis. The effects may provide some insights into the physiological activity of HIF and clinical medication safety."

Journal • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Nephrology • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Thrombosis • HIF1A

Efficacy and safety of prolyl hydroxylase inhibitors for anemia in chronic kidney disease: a network meta-analysis. (PubMed, Ren Fail) - "Roxadustat improved serum iron in D-CKD (MD = 6.19 μg/dL, 95% CI: 2.81-9.58), and vadadustat and roxadustat reduced hepcidin in ND-CKD. Regarding safety, ESA had the lowest AE risk in ND-CKD (OR = 0.85, 95% CI: 0.74-0.98), while roxadustat ranked lowest (SUCRA = 18.4%). Roxadustat demonstrated the strongest efficacy in hemoglobin improvement but higher AE incidence in ND-CKD, whereas ESA and daprodustat showed safety and iron metabolism benefits, supporting individualized therapy for renal anemia.Registration number: PROSPERO (CRD420251066181)."

Clinical • Journal • Retrospective data • Review • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

REDCURE Registry for Chronic Kidney Disease (CKD) Anemia (clinicaltrials.gov) - P4 | N=384 | Not yet recruiting | Sponsor: Nabiqasim Industries (Pvt) Ltd

HEOR • New P4 trial • Real-world evidence • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Daprodustat vs Recombinant Human Erythropoietin for Anemia and Cardiovascular Safety in Dialysis-Dependent and Non-Dialysis-Dependent CKD Patients - A Systematic Review and Meta-analysis. (PubMed, Curr Rev Clin Exp Pharmacol) - "Daprodustat offers a promising alternative to traditional anemia treatments in CKD, with efficacy comparable to rhEPO and a favorable cardiovascular safety profile, which marks its potential as a valuable therapeutic option."

Clinical • Journal • Retrospective data • Anemia • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) (clinicaltrials.gov) - P3 | N=100 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P3 trial • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

30 years of classical hematology drugs in the US: Approvals, costs, and sales (ASH 2025) - "Six drugs have been discontinued (year approved/year discontinued/reason): betrixaban(2017/2020/business), daprodustat (2023/2024/business), fidanacogene elaparvovec(2024/2025/business), oprelvekin (1997/2011/business), peginesatide (2012/2013/safety), and voxelotor(2019/2024/safety).There are limitations to our study. Some drugs have non-classical hematology indications (anticoagulantsin atrial fibrillation; luspatercept in myelodysplastic neoplasm) and/or may also be prescribed by non-classical hematologists (erythropoiesis stimulating agents by nephrologists and medical oncologists)...Classical hematology drugs contribute substantially to US prescription drug spending, with over $70billion in annual sales and medications for thromboembolism accounting for over half of the costs.Approvals have accelerated over the past three decades, doubling each decade. Biologics and biosimilarsnow represent two-thirds of approvals. Continuous-duration treatments, particularly for..."

Anemia • Atrial Fibrillation • Beta-Thalassemia • Cardiovascular • Chemotherapy-Induced Neutropenia • Chronic Kidney Disease • Complement-mediated Rare Disorders • Gene Therapies • Genetic Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hemophilia • Immune Thrombocytopenic Purpura • Immunology • Myelodysplastic Syndrome • Nephrology • Neutropenia • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Renal Disease • Sickle Cell Disease • Thrombocytopenia • Thrombocytopenic Purpura